Wakefield Asset Management LLLP Decreases Position in Tenet Healthcare Corporation $THC

Wakefield Asset Management LLLP decreased its position in Tenet Healthcare Corporation (NYSE:THC) by 17.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 21,143 shares of the company’s stock after selling 4,611 shares during the period. Tenet Healthcare comprises approximately 1.2% of Wakefield Asset Management LLLP’s portfolio, making the stock its 19th biggest holding. Wakefield Asset Management LLLP’s holdings in Tenet Healthcare were worth $4,293,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in THC. BNP Paribas Financial Markets lifted its position in shares of Tenet Healthcare by 4.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 183,124 shares of the company’s stock valued at $37,181,000 after buying an additional 8,588 shares during the last quarter. FourThought Financial Partners LLC bought a new stake in Tenet Healthcare in the 3rd quarter valued at about $320,000. Vestcor Inc lifted its holdings in Tenet Healthcare by 132.4% during the third quarter. Vestcor Inc now owns 13,986 shares of the company’s stock valued at $2,840,000 after purchasing an additional 7,969 shares during the last quarter. WINTON GROUP Ltd bought a new position in Tenet Healthcare during the third quarter worth about $7,748,000. Finally, Schroder Investment Management Group raised its position in shares of Tenet Healthcare by 165.8% in the third quarter. Schroder Investment Management Group now owns 40,497 shares of the company’s stock valued at $8,148,000 after purchasing an additional 25,262 shares during the period. 95.44% of the stock is currently owned by institutional investors.

Tenet Healthcare Trading Down 1.4%

NYSE THC opened at $237.30 on Wednesday. The company has a quick ratio of 1.68, a current ratio of 1.76 and a debt-to-equity ratio of 2.18. The stock’s 50-day simple moving average is $211.66 and its two-hundred day simple moving average is $203.29. Tenet Healthcare Corporation has a twelve month low of $109.82 and a twelve month high of $247.21. The company has a market capitalization of $20.64 billion, a price-to-earnings ratio of 15.32, a PEG ratio of 1.19 and a beta of 1.39.

Tenet Healthcare (NYSE:THC) last announced its quarterly earnings data on Wednesday, February 11th. The company reported $4.70 EPS for the quarter, beating the consensus estimate of $4.08 by $0.62. The firm had revenue of $5.53 billion for the quarter, compared to analyst estimates of $5.47 billion. Tenet Healthcare had a return on equity of 26.33% and a net margin of 6.60%.The company’s revenue was up 8.9% on a year-over-year basis. During the same period in the prior year, the company earned $3.44 EPS. Tenet Healthcare has set its FY 2026 guidance at 16.190-18.470 EPS. Research analysts forecast that Tenet Healthcare Corporation will post 12.24 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Nadja West sold 2,178 shares of Tenet Healthcare stock in a transaction on Monday, December 15th. The shares were sold at an average price of $197.47, for a total value of $430,089.66. Following the transaction, the director owned 28,480 shares in the company, valued at $5,623,945.60. This trade represents a 7.10% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Thomas W. Arnst sold 24,000 shares of the company’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $234.04, for a total transaction of $5,616,960.00. Following the sale, the executive vice president owned 8,012 shares of the company’s stock, valued at approximately $1,875,128.48. The trade was a 74.97% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 42,195 shares of company stock valued at $9,823,406. 0.81% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several research firms recently commented on THC. KeyCorp raised their price objective on shares of Tenet Healthcare from $225.00 to $250.00 and gave the stock an “overweight” rating in a report on Thursday, February 12th. Guggenheim raised their price target on Tenet Healthcare from $257.00 to $271.00 and gave the stock a “buy” rating in a report on Friday, February 13th. Royal Bank Of Canada boosted their price objective on Tenet Healthcare from $253.00 to $277.00 and gave the company an “outperform” rating in a research note on Thursday, February 12th. Weiss Ratings raised Tenet Healthcare from a “hold (c+)” rating to a “buy (b-)” rating in a report on Monday, December 29th. Finally, Jefferies Financial Group lifted their target price on Tenet Healthcare from $250.00 to $265.00 and gave the company a “buy” rating in a report on Thursday, February 12th. One research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Tenet Healthcare currently has an average rating of “Moderate Buy” and a consensus price target of $247.67.

Tenet Healthcare Profile

Tenet Healthcare Corporation (NYSE: THC) is a diversified American healthcare services company that owns and operates acute care hospitals and a broad range of outpatient facilities. Its portfolio includes general acute-care hospitals, specialty hospitals, ambulatory surgery centers, urgent care and diagnostic imaging centers, and other ancillary service locations. Tenet’s operations are oriented around delivering inpatient and outpatient clinical care across multiple medical specialties, with an emphasis on surgical services, emergency care, and advanced diagnostics.

In addition to facility-based care, Tenet provides integrated services designed to support clinical operations and improve patient access and care coordination.